Showing results (1001-1010 of 1,171) with videos related to
Sort By:
Pageof 118
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgeryXin-Rong Yang, Yang Xu, Bin Yu, et al.Journal of Hepatology|March 22, 2017
Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinomaAo Huang, Xin Zhao, Xin-Rong Yang, et al.Cancer Medicine|December 11, 2024
Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and FibrosisZhu-Tao Wang, Ruo-Yu Guan, Wei Gan, et al.Cell|April 3, 2018
Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor ProgressionYanmei Han, Qiuyan Liu, Jin Hou, et al.Journal of Hematology & Oncology|October 30, 2025
The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort studyDezhen Guo, Ao Huang, Jianlong Sun, et al.Clinical and Molecular Hepatology|March 18, 2026
Inactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic CholangiocarcinomaYe Xu, Kai-Xuan Liu, Xin-Yu Wang, et al.Cancer Discovery|July 24, 2023
An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic CholangiocarcinomaMao Zhang, Yingying Huang, Jiaomeng Pan, et al.BMC Cancer|May 11, 2018
PDXliver: a database of liver cancer patient derived xenograft mouse modelsSheng He, Bo Hu, Chao Li, et al.Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.Journal for Immunotherapy of Cancer|July 21, 2022
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilitiesJian Lin, Yuting Dai, Chen Sang, et al.Pageof 118